Chang Chih-Hao, Huang Shih-Hao, Huang Hung-Yu, Lin Meng-Hung, Lee Chung-Shu, Lee Hsin-Fu, Hsieh Jason Chia-Hsun, Cheng Chun-Yu
Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, New Taipei Municipal Tucheng Hospital, New Taipei City, Taiwan.
College of Medicine, Chang Gung University, Taoyuan City, Taiwan.
Ther Adv Med Oncol. 2024 Jan 18;16:17588359231221907. doi: 10.1177/17588359231221907. eCollection 2024.
Lung cancers are common worldwide. First-line targeted therapy and chemotherapy are both standard treatments in the current guidelines. With the development of new anticancer therapy, the lifespan of patients with late-stage lung cancer has increased. Cardiovascular events can occur during cancer treatment. This observational study aimed to report the incidence of major adverse cardiovascular events (MACE) after cancer treatment using real-world data.
Patients diagnosed with advanced-stage lung cancer between January 2011 and December 2017 were enrolled. Data were collected from the Chang Gung Research Database (CGRD).
Retrospective cohort study.
Baseline characteristics, clinical stages, pathologies, and outcomes were retrieved from the CGRD.
We identified 4406 patients with advanced lung cancer, of whom 2197 received first-line epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) therapy and 2209 received first-line platinum-based chemotherapy. Most patients in the first-line EGFR-TKI group were never-smokers (74.9%), whereas those in the first-line chemotherapy group were ever-smokers (66.0%). The incidence of MACE was not significantly different between the two groups (12.0% 11.9%, = 0.910). However, the incidence of ischemic stroke was higher in the first-line EGFR-TKI group than in the first-line chemotherapy group (3.9% 1.9%, < 0.001).
MACEs are common in patients with advanced-stage lung cancer during treatment. The incidence of MACE was similar between the first-line EGFR-TKI therapy and first-line chemotherapy groups. Although more patients in the EGFR-TKI group were female and never-smokers, the risk of ischemic stroke was higher in patients who received first-line EGFR-TKI therapy than in those who received first-line chemotherapy.
肺癌在全球范围内都很常见。一线靶向治疗和化疗都是当前指南中的标准治疗方法。随着新型抗癌疗法的发展，晚期肺癌患者的生存期有所延长。癌症治疗期间可能会发生心血管事件。这项观察性研究旨在利用真实世界数据报告癌症治疗后主要不良心血管事件（MACE）的发生率。
纳入2011年1月至2017年12月期间诊断为晚期肺癌的患者。数据来自长庚研究数据库（CGRD）。
回顾性队列研究。
从CGRD中检索基线特征、临床分期、病理和结局。
我们确定了4406例晚期肺癌患者，其中2197例接受一线表皮生长因子受体酪氨酸激酶抑制剂（EGFR-TKI）治疗，2209例接受一线铂类化疗。一线EGFR-TKI组的大多数患者从不吸烟（74.9%），而一线化疗组的患者曾经吸烟（66.0%）。两组之间MACE的发生率无显著差异（12.0%对11.9%，P = 0.910）。然而，一线EGFR-TKI组的缺血性卒中发生率高于一线化疗组（3.9%对1.9%，P < 0.001）。
MACE在晚期肺癌患者治疗期间很常见。一线EGFR-TKI治疗组和一线化疗组之间MACE的发生率相似。虽然EGFR-TKI组中女性和从不吸烟的患者更多，但接受一线EGFR-TKI治疗的患者发生缺血性卒中的风险高于接受一线化疗的患者。
